Shanghai Allist Pharmaceuticals Co., Ltd. Stock

Equities

688578

CNE100005XJ7

Biotechnology & Medical Research

End-of-day quote Shanghai S.E. 06:00:00 2024-05-07 pm EDT 5-day change 1st Jan Change
64.62 CNY -2.18% Intraday chart for Shanghai Allist Pharmaceuticals Co., Ltd. +4.09% +55.11%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Sales 2023 2.01B 279M Sales 2024 * 2.98B 412M Capitalization 29.08B 4.03B
Net income 2023 645M 89.29M Net income 2024 * 1.05B 146M EV / Sales 2023 9.32 x
Net cash position 2023 * - 0 Net cash position 2024 * - 0 EV / Sales 2024 * 9.76 x
P/E ratio 2023
29.1 x
P/E ratio 2024 *
27.6 x
Employees 870
Yield 2023
0.96%
Yield 2024 *
0.77%
Free-Float 34.03%
More Fundamentals * Assessed data
Dynamic Chart
1 day-2.18%
1 week+4.09%
Current month+4.09%
1 month+40.26%
3 months+60.55%
6 months+72.37%
Current year+55.11%
More quotes
1 week
62.15
Extreme 62.15
68.87
1 month
44.88
Extreme 44.88
68.87
Current year
32.25
Extreme 32.25
68.87
1 year
22.16
Extreme 22.16
68.87
3 years
14.81
Extreme 14.81
68.87
5 years
14.81
Extreme 14.81
68.87
10 years
14.81
Extreme 14.81
68.87
More quotes
Managers TitleAgeSince
Chief Executive Officer 70 04-03-21
Director/Board Member 59 16-12-31
Director/Board Member 49 19-06-24
Members of the board TitleAgeSince
Director/Board Member 42 19-11-27
Chief Executive Officer 70 04-03-21
Director/Board Member 39 19-11-27
More insiders
Date Price Change Volume
24-05-08 64.62 -2.18% 9,710,229
24-05-07 66.06 -2.25% 13,654,040
24-05-06 67.58 +8.86% 16,658,250
24-04-30 62.08 +7.26% 18,346,980

End-of-day quote Shanghai S.E., May 07, 2024

More quotes
Shanghai Allist Pharmaceuticals Co Ltd is a China-based company focusing on the field of tumor treatment. The Company has built a research and development pipeline in the field of small molecule targeted drugs for non-small cell lung cancer. The Company has established a complete new drug research and development system, covering all aspects of lead drug discovery and optimization, candidate drug evaluation and establishment, drug preclinical and clinical research, drug registration and application, industrialization and commercialization. The Company has a number of research pipeline projects under development, such as vometinib. Its drugs are used in the fields of blood pressure reduction, anti-tumor, anti-diabetic and gastric acid related diseases.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
64.62
Average target price
-
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 688578 Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW